Anika Therapeutics (ANIK) Other Accumulated Expenses (2011 - 2026)

Anika Therapeutics (ANIK) has 15 years of Other Accumulated Expenses data on file, last reported at $479000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 38.27% year-over-year to $479000.0 in Q1 2026; TTM through Mar 2026 was $479000.0, a 38.27% decrease from a year earlier, with the FY2025 full-year figure at $468000.0, down 38.82% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $479000.0, up from $468000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for ANIK reached as high as $1.1 million in Q1 2022 and fell as low as $338000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $611941.2 across 5 years, with a median of $517000.0 in 2024.
• Across the five-year window, Other Accumulated Expenses slumped 97.14% in 2022 and soared 126.33% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $510000.0 in 2022, then tumbled by 33.73% to $338000.0 in 2023, then jumped by 126.33% to $765000.0 in 2024, then sank by 38.82% to $468000.0 in 2025, then grew by 2.35% to $479000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $479000.0 in Q1 2026, $468000.0 in Q4 2025, and $750000.0 in Q3 2025.